The Prevalence and Concurrent Pathogenic Mutations of KRAS(G12C) in Northeast Chinese Non-small-cell Lung Cancer Patients

OBJECTIVE: KRAS mutation is one of important driver genes in non-small-cell lung cancer (NSCLC) and the patients with KRAS(G12C) mutations benefit from the inhibitor AMG510. However, the frequency, concurrent pathogenic mutations, and clinical characteristic of KRAS(G12C) is unknown in the NSCLC pop...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yan, Li, Hui, Zhu, Jing, Zhang, Yang, Liu, Xianhong, Li, Rixin, Zhang, Qiang, Cheng, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979353/
https://www.ncbi.nlm.nih.gov/pubmed/33758543
http://dx.doi.org/10.2147/CMAR.S282617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979353/
https://www.ncbi.nlm.nih.gov/pubmed/33758543
http://dx.doi.org/10.2147/CMAR.S282617

Ejemplares similares